IO Biotech Regains Nasdaq Compliance with Stock Price

IO Biotech ( (IOBT) ) has issued an update.

IO Biotech, Inc. faced a compliance issue with Nasdaq’s minimum bid price requirement when its stock price fell below $1.00 per share for 30 consecutive trading days as of December 26, 2024. However, by June 3, 2025, the company successfully regained compliance as its stock price reached $1.00 or more for at least 10 consecutive business days, resolving the matter with Nasdaq.

The most recent analyst rating on (IOBT) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on IO Biotech stock, see the IOBT Stock Forecast page.

Spark’s Take on IOBT Stock

According to Spark, TipRanks’ AI Analyst, IOBT is a Neutral.

IO Biotech faces significant challenges due to its financial instability and lack of revenue. However, the progress in clinical trials and secured financing improve its future prospects, though it remains speculative. The technical analysis suggests neutral momentum, and the valuation highlights typical risks associated with biotech stocks awaiting commercialization.

To see Spark’s full report on IOBT stock, click here.

More about IO Biotech

Average Trading Volume: 173,635

Technical Sentiment Signal: Buy

Current Market Cap: $106.7M

For a thorough assessment of IOBT stock, go to TipRanks’ Stock Analysis page.